Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

MYGN

Myriad Genetics, Inc

Mar 21 • 04:00PM ET

10.01

Dollar change +0.10
Percentage change 1.01	%

Healthcare • Diagnostics & Research • USA • NASD

Peers: ILMN GH INCY QGEN EXAS NTLA CRSP CDNA TXG TWST

| Held by: IJR VTI IWM VB XBI VXF IJS IWN SPSM VBR

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-1.40	Insider Own	3.88%	Shs Outstand	91.30M	Perf Week	-0.60%
Market Cap	914.00M	Forward P/E	41.16	EPS next Y	0.24	Insider Trans	-0.42%	Shs Float	87.76M	Perf Month	-33.18%
Income	-127.30M	PEG	-	EPS next Q	-0.05	Inst Own	101.81%	Short Float	5.59%	Perf Quarter	-27.57%
Sales	837.60M	P/S	1.09	EPS this Y	-69.92%	Inst Trans	1.67%	Short Ratio	4.54	Perf Half Y	-64.84%
Book/sh	7.68	P/B	1.30	EPS next Y	477.54%	ROA	-11.20%	Short Interest	4.91M	Perf Year	-53.66%
Cash/sh	1.22	P/C	8.23	EPS next 5Y	42.20%	ROE	-17.15%	52W Range	9.36 - 29.30	Perf YTD	-26.99%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-15.36%	52W High	-65.84%	Beta	1.83
Dividend TTM	-	Quick Ratio	1.65	Sales past 5Y	6.82%	Gross Margin	66.08%	52W Low	6.94%	ATR (14)	0.68
Dividend Ex-Date	-	Current Ratio	1.82	EPS Y/Y TTM	56.19%	Oper. Margin	-10.65%	RSI (14)	36.96	Volatility	3.88% 6.86%
Employees	2700	Debt/Eq	0.20	Sales Y/Y TTM	11.21%	Profit Margin	-15.20%	Recom	2.53	Target Price	17.09
Option/Short	Yes / Yes	LT Debt/Eq	0.18	EPS Q/Q	-28.73%	Payout	-	Rel Volume	1.76	Prev Close	9.91
Sales Surprise	-0.48%	EPS Surprise	-1.32%	Sales Q/Q	7.12%	Earnings	Feb 24 AMC	Avg Volume	1.08M	Price	10.01
SMA20	-4.95%	SMA50	-17.88%	SMA200	-49.96%	Trades		Volume	1,905,017	Change	1.01%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-12-25	Upgrade	Piper Sandler	Neutral → Overweight	$11.50 → $12.50
Feb-12-25	Initiated	Craig Hallum	Buy	$29
Dec-10-24	Initiated	UBS	Neutral	$18
Dec-09-24	Downgrade	Leerink Partners	Outperform → Market Perform	$30 → $21
Sep-19-24	Initiated	Morgan Stanley	Equal-Weight	$32
Aug-28-24	Initiated	Wells Fargo	Overweight	$35
Jun-27-24	Initiated	Scotiabank	Sector Outperform	$29
Jun-03-24	Resumed	Jefferies	Underperform	$20
May-08-24	Upgrade	Leerink Partners	Market Perform → Outperform	$25 → $35
Dec-21-23	Resumed	Piper Sandler	Neutral	$23
Dec-19-23	Initiated	Wells Fargo	Equal Weight	$20
Dec-14-23	Initiated	Guggenheim	Buy	$23
Dec-13-23	Initiated	Wolfe Research	Outperform	$28
Jul-05-23	Resumed	JP Morgan	Underweight	$18
May-23-23	Upgrade	Goldman	Sell → Buy	$18 → $25
Jan-18-23	Upgrade	Raymond James	Mkt Perform → Outperform	$25
Oct-06-22	Initiated	Stephens	Equal-Weight	$22
Oct-15-21	Resumed	Cowen	Market Perform	$33
Jun-15-21	Initiated	Raymond James	Mkt Perform
Jun-03-21	Initiated	Goldman	Sell	$25

Show Previous Ratings

Mar-21-25 08:30AM	Artisan International Small-Mid Fund Q4 2024 Commentary (SeekingAlpha)
Mar-19-25 05:05AM	A Look Back at Therapeutics Stocks Q4 Earnings: Vertex Pharmaceuticals (NASDAQ:VRTX) Vs The Rest Of The Pack (StockStory)
Mar-17-25 05:10AM	Myriad Genetics (MYGN): Buy, Sell, or Hold Post Q4 Earnings? (StockStory)
Mar-12-25 01:17PM	Why Are Myriad Genetics (MYGN) Shares Soaring Today (StockStory)
Mar-11-25 05:03AM	Winners And Losers Of Q4: Myriad Genetics (NASDAQ:MYGN) Vs The Rest Of The Therapeutics Stocks (StockStory) +6.77%
04:03AM	Loading…
Mar-04-25 04:03AM	Spotting Winners: Sarepta Therapeutics (NASDAQ:SRPT) And Therapeutics Stocks In Q4 (StockStory)
Feb-27-25 04:15PM	Myriad Genetics and Gabbi to Work Together to Increase Access to Hereditary Cancer Risk Assessment Tools (GlobeNewswire)
Feb-25-25 02:07PM	Why Myriad Genetics (MYGN) Shares Are Plunging Today (StockStory) -14.80%
10:25AM	Myriad Genetics, Inc. (MYGN): AI-Driven Precision Medicine for Prostate Cancer (Insider Monkey)
07:59AM	Q4 2024 Myriad Genetics Inc Earnings Call (Thomson Reuters StreetEvents)
02:03AM	Myriad Genetics Inc (MYGN) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com)
Feb-24-25 07:00PM	Myriad (MYGN) Reports Q4 Earnings: What Key Metrics Have to Say (Zacks)
06:00PM	Myriad Genetics (MYGN) Meets Q4 Earnings Estimates (Zacks)
05:11PM	Myriad: Q4 Earnings Snapshot (Associated Press Finance)
04:31PM	Myriad Genetics (NASDAQ:MYGN) Misses Q4 Sales Targets, Stock Drops (StockStory)
04:05PM	Loading…
04:05PM	Myriad Genetics Reports Fourth Quarter and Full-Year 2024 Financial Results; Full-year 2024 revenue of $838 million grew 11% year-over-year, the second consecutive year of double-digit revenue growth (GlobeNewswire)
04:05PM	Myriad Genetics Announces Senior Leadership Transition (GlobeNewswire)
08:30AM	Myriad Genetics Partners with PATHOMIQ to add Artificial Intelligence Technology Platform to its Oncology Portfolio (GlobeNewswire)
Feb-23-25 08:01AM	What To Expect From Myriad Geneticss (MYGN) Q4 Earnings (StockStory)
Feb-19-25 08:30AM	Myriad Genetics Included in Forbes America's Best Employers 2025 List (GlobeNewswire)
Feb-18-25 08:30AM	Myriad Genetics to Release Fourth Quarter and Full Year 2024 Financial Results on February 24, 2025 (GlobeNewswire)
Feb-17-25 06:05AM	3 Reasons to Sell MYGN and 1 Stock to Buy Instead (StockStory)
Feb-06-25 08:30AM	Myriad Genetics and CancerCARE for Life Announce Agreement to Advance Access to MyRisk with RiskScore Hereditary Cancer Test (GlobeNewswire)
Feb-05-25 04:15PM	Myriad Genetics Announces Two New Patents Granted for its Molecular Residual Disease (MRD) Assay (GlobeNewswire)
08:30AM	Myriad Genetics and Lumea Collaborate to Enhance Access to the Prolaris Biomarker and MyRisk Hereditary Cancer Tests through BxLink Integration (GlobeNewswire)
Jan-29-25 08:30AM	Myriad Genetics Unveils Groundbreaking Eight Weeks' Gestation NIPT Study Results at Society for Maternal-Fetal Medicine Conference (GlobeNewswire)
Jan-24-25 08:08PM	Why Is Larry Robbins Bullish on Myriad Genetics, Inc. (MYGN) Now? (Insider Monkey)
Jan-23-25 08:30AM	Myriad Genetics Introduces Online Prenatal Genetic Testing Resource (GlobeNewswire)
Jan-21-25 08:30AM	Myriad Genetics Announces Hereditary Cancer Risk Assessment Program Study Published in Obstetrics & Gynecology (GlobeNewswire)
Jan-15-25 08:30AM	Myriad Genetics Announces Select Preliminary Fourth Quarter and Full Year 2024 Financial Results and Introduces Full Year 2025 Financial Guidance (GlobeNewswire)
04:30PM	Loading…
Jan-09-25 04:30PM	Myriad Genetics Signs Agreement with Nationally Renowned Sports Broadcaster Hannah Storm to Promote the Importance of Knowing Family Cancer History (GlobeNewswire)
Jan-08-25 11:27AM	UPDATE Myriad Genetics to Present at 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
08:00AM	Myriad Genetics to Present at 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Jan-07-25 08:00AM	MD Anderson and Myriad Genetics form strategic alliance to evaluate clinical utility of Myriad's molecular residual disease assay (GlobeNewswire)
Jan-06-25 08:00AM	Myriad Genetics Issues Quality, Innovation, and Corporate Responsibility Report (GlobeNewswire)
Dec-19-24 04:15PM	Myriad Genetics' RiskScore Study Named One of the Top 10 Significant Advances in Genomic Medicine in American Journal of Human Genetics (GlobeNewswire)
Dec-10-24 06:26PM	Myriad Genetics Provides Update on Discussions with UnitedHealthcare regarding Medical Policy for Pharmacogenetic Testing (GlobeNewswire) -5.41%
04:05PM	Myriad Genetics Expands Board of Directors with Election of Mark S. Davis as New Board Member (GlobeNewswire)
08:00AM	Myriad Genetics' Portfolio Elevated by Updated NCCN Prostate Cancer Guidelines (GlobeNewswire)
Dec-09-24 04:05PM	Myriad Genetics to Present New Data at San Antonio Breast Cancer Symposium (GlobeNewswire)
08:00AM	NCCN Prostate Cancer Guidelines Reinforce Status of Myriad Genetics' Prolaris Test as an 'Advanced Tool' Recommended for Prognostic Assessment (GlobeNewswire)
Nov-20-24 04:30PM	Myriad Genetics Announces Incorporation of its Proprietary HRD platform in Illumina's Updated Comprehensive Gene Panel Assay, TruSight Oncology 500 v2 (GlobeNewswire)
Nov-19-24 08:00AM	Myriad Genetics Announces Prequel Prenatal Screening Can Now be Performed Eight Weeks into Pregnancy (GlobeNewswire)
07:27AM	Myriad Genetics price target lowered to $21 from $32 at Morgan Stanley (TipRanks)
Nov-13-24 08:00AM	Myriad Genetics Expands Access to At-Home Early Fetal Sex DNA Test with Retail Launch (GlobeNewswire)
Nov-08-24 02:26AM	Myriad Genetics Inc (MYGN) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid Policy ... (GuruFocus.com)
Nov-07-24 06:30PM	Compared to Estimates, Myriad (MYGN) Q3 Earnings: A Look at Key Metrics (Zacks)
06:00PM	Myriad Genetics (MYGN) Q3 Earnings and Revenues Surpass Estimates (Zacks)
05:02PM	Myriad: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Myriad Genetics Reports Third Quarter 2024 Financial Results; Updates 2024 Financial Guidance (GlobeNewswire)
Nov-04-24 08:39AM	Myriad Genetics Comments on UnitedHealthcare's Updated Medical Policy for Pharmacogenetic Testing (GlobeNewswire)
Nov-02-24 11:15AM	Myriad weakness due to UnitedHealth coverage update, says Stephens (TipRanks)
Nov-01-24 06:55PM	Analyst Report: Myriad Genetics, Inc. (Morningstar Research) -18.08%
Oct-30-24 08:00AM	Myriad Genetics to Release Third Quarter 2024 Financial Results on November 7, 2024 (GlobeNewswire)
Oct-28-24 10:01AM	Myriad Genetics (MYGN) Earnings Expected to Grow: Should You Buy? (Zacks)
Oct-22-24 02:19PM	Analyst Report: Myriad Genetics, Inc. (Morningstar Research)
Oct-16-24 09:00AM	Myriad Genetics and jscreen Announce Strategic Partnership to Advance Health Equity and Genetic Testing Access (GlobeNewswire)
Oct-15-24 09:00AM	Myriad Genetics and Flatiron Health Partner to Make Genetic Testing More Accessible with Electronic Medical Record Integration (GlobeNewswire)
Oct-09-24 07:49AM	Myriad signs five partnerships to study MRD testing in breast cancer (Clinical Trials Arena) -6.12%
Oct-08-24 04:05PM	Myriad Genetics Announces Five Research Collaborations to Study the Use of MRD Testing in Breast Cancer (GlobeNewswire)
Oct-04-24 06:33AM	Myriad and Ultima to study UG 100 sequencing platform for genomics clinical tests (Medical Device Network)
Oct-03-24 09:00AM	Myriad Genetics and Ultima Genomics to Explore the UG 100 Sequencing Platform to Advance Clinical Test Offerings in Oncology and Reproductive Genomics (GlobeNewswire)
Oct-01-24 04:05PM	Myriad Genetics Announces Third Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date (GlobeNewswire)
Sep-25-24 06:38PM	Analyst Report: Myriad Genetics, Inc. (Morningstar Research)
Sep-18-24 09:50AM	Here's Why Myriad Genetics (MYGN) is a Strong Momentum Stock (Zacks)
08:00AM	Myriad Genetics to Share New Data Highlighting Genetic Testing Advancements at 2024 National Society of Genetic Counselors Annual Conference (GlobeNewswire)
Sep-16-24 06:37PM	Analyst Report: Myriad Genetics, Inc. (Morningstar Research)
Sep-13-24 01:54AM	Insider Sale: Chief Scientific Officer Dale Muzzey Sells Shares of Myriad Genetics Inc (MYGN) (GuruFocus.com)
01:54AM	Insider Sale: President and CEO Paul Diaz Sells 15,000 Shares of Myriad Genetics Inc (MYGN) (GuruFocus.com)
Sep-10-24 01:17AM	Insider Sale: Director Heinrich Dreismann Sells Shares of Myriad Genetics Inc (MYGN) (GuruFocus.com)
Sep-05-24 11:31AM	Myriad (MYGN) Down 4.8% Since Last Earnings Report: Can It Rebound? (Zacks) +9.07%
08:00AM	Myriad Genetics to Host Investor Event on October 9, 2024 (GlobeNewswire)
01:33AM	Insider Sale: Director Colleen Reitan Sells Shares of Myriad Genetics Inc (MYGN) (GuruFocus.com)
Sep-04-24 06:50PM	Analyst Report: Myriad Genetics, Inc. (Morningstar Research) -7.65%
Aug-30-24 09:50AM	Why Myriad Genetics (MYGN) is a Top Momentum Stock for the Long-Term (Zacks)
Aug-23-24 07:01PM	Insider Sale at Myriad Genetics Inc (MYGN): SVP, Chief of Staff Margaret Ancona Sells Shares (GuruFocus.com)
Aug-21-24 08:00AM	Myriad Genetics to Participate in Two Upcoming Investor Healthcare Conferences (GlobeNewswire)
Aug-20-24 07:01PM	Insider Sale: Director Rashmi Kumar Sells 7,500 Shares of Myriad Genetics Inc (MYGN) (GuruFocus.com)
Aug-09-24 07:07PM	Analyst Report: Myriad Genetics, Inc. (Morningstar Research)
Aug-08-24 08:16AM	Myriad Genetics (MYGN) Q2 Earnings Surpass, '24 Outlook Raised (Zacks)
Aug-07-24 10:36PM	Analyst Report: Myriad Genetics, Inc. (Morningstar Research)
Aug-06-24 07:00PM	Myriad (MYGN) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
06:30PM	Myriad Genetics (MYGN) Surpasses Q2 Earnings and Revenue Estimates (Zacks)
05:28PM	Myriad: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Myriad Genetics Reports Strong Second Quarter 2024 Financial Results, including 15% Revenue Growth Year-Over-Year; Raises 2024 Financial Guidance and Long-Term Revenue Growth Target to 12% (GlobeNewswire)
Aug-01-24 04:05PM	Myriad Genetics Advances International Reorganization and Completes Sale of EndoPredict Business to Eurobio Scientific (GlobeNewswire)
Jul-31-24 08:50AM	Myriad Genetics Appoints Jennifer Fox as Chief Legal Officer (GlobeNewswire)
Jul-30-24 08:00AM	Myriad Genetics to Release Second Quarter 2024 Financial Results on August 6, 2024 (GlobeNewswire)
Jul-17-24 08:00AM	What We Don't Know Can Hurt: New Cancer Risk Survey from Myriad Genetics Reveals Serious Knowledge Gaps About Breast Density and Cancer Risk (GlobeNewswire)
Jul-15-24 02:01PM	Myriad Genetics (MYGN) Expands in MRD Testing With New Collab (Zacks)
Jul-11-24 09:00AM	Myriad Genetics and Personalis Cross-License Foundational MRD Intellectual Property to Broaden Patient Access to Testing (GlobeNewswire)
Jul-10-24 07:53AM	Myriad Genetics (MYGN) Advances in MRD Space With New Patent (Zacks)
Jul-09-24 09:00AM	Myriad Genetics Announces Second Foundational Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date (GlobeNewswire)
Jul-08-24 09:00AM	The 3 Best Gene Editing Stocks to Buy in July 2024 (InvestorPlace)
Jul-03-24 07:07PM	Analyst Report: Myriad Genetics, Inc. (Morningstar Research)
Jul-02-24 09:00AM	Myriad Genetics Earns 2024 Great Place To Work Certification (GlobeNewswire)
Jun-24-24 04:05PM	Survey Suggests Increased Attention on Mental Health Warranted in the Run-Up to the Election (GlobeNewswire)
Jun-12-24 11:46AM	Myriad Genetics (MYGN) and GSK Unite to Boost HRD Testing (Zacks)
Jun-11-24 09:36AM	Myriad Genetics (MYGN) Banks on Innovation Amid Macro Woes (Zacks)
08:00AM	Myriad Genetics Collaborates with GSK to Improve Access to HRD Testing in 9 Countries (GlobeNewswire)

Myriad Genetics, Inc. engages in the discovery, development, and marketing of transformative molecular diagnostic tests. It operates through the Diagnostics and Other segments. The Diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual's risk of developing a disease later in life. The Other segment offers testing products and services to the pharmaceutical, biotechnology and medical research industries, research and development, and clinical services for patients, and also includes corporate services. The company was founded by Walter A. Gilbert, Mark H. Skolnick, and Peter D. Meldrum in May 1991 and is headquartered in Salt Lake City, UT.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
DIAZ PAUL J	President and CEO	Oct 11 '24	Sale	22.93	15,000	343,950	962,378	Oct 11 05:23 PM
DIAZ PAUL J	Officer	Oct 11 '24	Proposed Sale	22.93	15,000	343,950		Oct 11 10:35 AM
Ancona Margaret	Officer	Aug 21 '24	Proposed Sale	27.82	11,538	321,019		Sep 16 02:30 PM
DIAZ PAUL J	President and CEO	Sep 11 '24	Sale	26.72	15,000	400,800	977,378	Sep 12 04:11 PM
Muzzey Dale	Chief Scientific Officer	Sep 11 '24	Sale	26.17	2,100	54,961	108,013	Sep 12 04:09 PM
Muzzey Dale	Officer	Sep 11 '24	Proposed Sale	26.17	2,100	54,961		Sep 11 03:26 PM
DIAZ PAUL J	Officer	Sep 11 '24	Proposed Sale	26.72	15,000	400,800		Sep 11 10:05 AM
Dreismann Heinrich	Director	Sep 09 '24	Sale	27.05	10,000	270,520	121,648	Sep 09 05:48 PM
Dreismann Heinrich	Director	Sep 10 '24	Proposed Sale	27.00	10,000	270,000		Sep 09 02:52 PM
Reitan Colleen F	Director	Sep 03 '24	Sale	27.95	46,012	1,285,851	42,533	Sep 04 07:38 PM
Reitan Colleen F	Director	Sep 03 '24	Proposed Sale	28.19	46,012	1,297,078		Sep 03 10:11 AM
Ancona Margaret	SVP, Chief of Staff	Aug 21 '24	Sale	27.82	11,538	320,987	79,366	Aug 23 04:16 PM
Kumar Rashmi	Director	Aug 19 '24	Sale	28.01	7,500	210,075	77,392	Aug 20 04:38 PM
Kumar Rashmi	Director	Aug 19 '24	Proposed Sale	28.01	7,500	210,075		Aug 19 02:46 PM
SPIEGELMAN DANIEL K	Director	Jun 04 '24	Sale	22.05	3,788	83,525	32,917	Jun 04 05:57 PM
SPIEGELMAN DANIEL K	Director	Jun 03 '24	Sale	22.04	3,788	83,488	36,705	Jun 04 05:57 PM
DIAZ PAUL J	President and CEO	May 14 '24	Sale	25.21	95,000	2,394,798	1,141,166	May 15 05:49 PM
DIAZ PAUL J	President and CEO	May 15 '24	Sale	25.07	75,000	1,880,415	1,066,166	May 15 05:49 PM
DIAZ PAUL J	President and CEO	May 13 '24	Sale	25.13	57,844	1,453,550	1,236,166	May 15 05:49 PM
Newcomer Lee Nisley	Director	May 13 '24	Sale	25.30	6,200	156,860	66,650	May 15 05:48 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

MYGN

Myriad Genetics, Inc

Upgrade your FINVIZ experience